Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons
2018/07/09 by Darios Getahun, Rebecca Nash, W. Dana Flanders +17 · 33 citations
Psychology · Medicine · #LGBTQ Health, Identity, and Policy #Sex and Gender in Healthcare #Bariatric Surgery and Outcomes
paper · doi:10.7326/m17-2785
Abstract
Background: Venous thromboembolism (VTE), ischemic stroke, and myocardial infarction in transgender persons may be related to hormone use. Objective: To examine the incidence of these events in a cohort of transgender persons. Design: Electronic medical record-based cohort study of transgender members of integrated health care systems who had an index date (first evidence of transgender status) from 2006 through 2014. Ten male and 10 female cisgender enrollees were matched to each transgender participant by year of birth, race/ethnicity, study site, and index date enrollment. Setting: Kaiser Permanente in Georgia and northern and southern California. Patients: 2842 transfeminine and 2118 transmasculine members with a mean follow-up of 4.0 and 3.6 years, respectively, matched to 48 686 cisgender men and 48 775 cisgender women. Measurements: VTE, ischemic stroke, and myocardial infarction events ascertained from diagnostic codes through the end of 2016 in transgender and reference cohorts. Results: Transfeminine participants had a higher incidence of VTE, with 2- and 8-year risk differences of 4.1 (95% CI, 1.6 to 6.7) and 16.7 (CI, 6.4 to 27.5) per 1000 persons relative to cisgender men and 3.4 (CI, 1.1 to 5.6) and 13.7 (CI, 4.1 to 22.7) relative to cisgender women. The overall analyses for ischemic stroke and myocardial infarction demonstrated similar incidence across groups. More pronounced differences for VTE and ischemic stroke were observed among transfeminine participants who initiated hormone therapy during follow-up. The evidence was insufficient to allow conclusions regarding risk among transmasculine participants. Limitation: Inability to determine which transgender members received hormones elsewhere. Conclusion: The patterns of increases in VTE and ischemic stroke rates among transfeminine persons are not consistent with those observed in cisgender women. These results may indicate the need for long-term vigilance in identifying vascular side effects of cross-sex estrogen. Primary Funding Source: Patient-Centered Outcomes Research Institute and Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Citations
Cited by
- Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
- Effect of Medical Interventions on Body Satisfaction in Gender-Dysphoric Adolescents
- The Impact of Gender-Affirming Hormone Therapy on Physical Performance
- Musculoskeletal and cardiovascular considerations for transgender athletes
- Estrogen and thrombosis: A bench to bedside review
- Impact of the use of self-perceived gender identity versus biological gender on the interpretation of laboratory tests: clinical and safety implications intransgender individuals
- Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy
- Insulin resistance in transgender individuals correlates with android fat mass
- The Relationship Between Tobacco Use and Legal Document Gender-Marker Change, Hormone Use, and Gender-Affirming Surgery in a United States Sample of Trans-Feminine and Trans-Masculine Individuals: Implications for Cardiovascular Health. [europepmc]
- Assessment of Internal Medicine Resident Preparedness to Care for Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning Patients. [europepmc]
- Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. [europepmc]
- Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS. [europepmc]
- Sex and the kidneys: current understanding and research opportunities. [europepmc]
- Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. [europepmc]
- Mental Health Diagnoses Among Transgender Patients in the Clinical Setting: An All-Payer Electronic Health Record Study. [europepmc]
- Individualized medicine: Sex, hormones, genetics, and adverse drug reactions. [europepmc]
- Impact of Exogenous Testosterone on Reproduction in Transgender Men. [europepmc]
- Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. [europepmc]
- The impact of sex and gender on immunotherapy outcomes. [europepmc]
- Clinical trials for COVID-19 should include sex as a variable. [europepmc]
- Estrogen and thrombosis: A bench to bedside review. [europepmc]
- Covid-19 Kills More Men Than Women: An Overview of Possible Reasons. [europepmc]
- Assessing and Addressing Cardiovascular Health in LGBTQ Adults: A Scientific Statement From the American Heart Association. [europepmc]
- Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. [europepmc]
- Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. [europepmc]
- Sexual and Gender Minority Health in Neurology: A Scoping Review. [europepmc]
- Cardiovascular Disease in a Population-Based Sample of Transgender and Cisgender Adults. [europepmc]
- Sex Differences in Myocardial and Vascular Aging. [europepmc]
- The Impact of Sex and Gender on Stroke. [europepmc]
- The impact of biological sex on diseases of the urinary tract. [europepmc]
- The Effect of Gender-Affirming Hormone Therapy on Measures of Kidney Function: A Systematic Review and Meta-Analysis. [europepmc]
- Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. [europepmc]
- Impact of biological sex and sex hormones on molecular signatures of skeletal muscle at rest and in response to distinct exercise training modes. [europepmc]
Related